Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation syndrome

  title={Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation syndrome},
  author={Dwight R. Stickney and Jessie R. Groothuis and Clarence N. Ahlem and Michael R. Kennedy and B Miller and Nanette Onizuka-Handa and Karen M Schlangen and Daniel A. Destiche and Christopher L Reading and Armando Garsd and James M. Frincke},
  journal={Journal of Radiological Protection},
  pages={687 - 698}
5-androstenediol (5-AED) has been advanced as a possible countermeasure for treating the haematological component of acute radiation syndrome (ARS). It has been used in animal models to stimulate both innate and adaptive immunity and treat infection and radiation-induced immune suppression. We here report on the safety, tolerability and haematologic activity of 5-AED in four double-blinded, randomized, placebo-controlled studies on healthy adults including elderly subjects. A 5-AED injectable… 

Radiation Countermeasures: Current Status

This review gives an overview on various radioprotectors, radiomitigators and therapeutic agents either available or under development currently.

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

In recent times, cytokines and hematopoietic growth factors have been at the center of attention for many researchers trying to establish pharmacological therapeutic procedures for the treatment of

Use of Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency.

The NIAID partnered with the Radiation Injury Treatment Network (RITN), whose membership includes medical centers with expertise in the management of bone marrow failure, to explore the use of growth factors and other cytokines as MCMs to mitigate/treat radiation injuries.

New pharmacological means of radiation protection (literature review)

  • Nataliya Uzlenkova
  • Medicine
  • 2019
The review systematized the current data on new classes of pharmacological compounds and biologically active substances in the field of radiation protection in Ukraine, as well as abroad and presented results of the effectiveness of tolerant antioxidants with a wide spectrum of biological activity as promising agents for the prevention of acute and delayed radiation-induced pathology.

5-Androstenediol prevents radiation injury in mice by promoting NF-κB signaling and inhibiting AIM2 inflammasome activation.

5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis

The results suggest 5-AED survival enhancement is G-CSF-dependent, and that it stimulates innate immune cell function and reduces radiation-induced DNA damage via induction of genes that modulate cell cycle progression and apoptosis.

A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status

There are a limited number of countermeasures which are progressing well following the Animal Rule and may get approved in the near future, thus serving to close the gap of this critically important, unmet radiobiomedical need.

Radiation countermeasure agents: an update (2011 – 2014)

G-CSF has high potential and well-documented therapeutic effects in countering myelosuppression and may receive full licensing approval by the US FDA in the future.

A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute

In this communication, selected promising radiation countermeasures at advanced stages of development are discussed and the in vivo efficacy of selected countermeasures in animal models and clinical studies are reviewed.



HE2100 (5-Androstene-3β,17β-diol) after Cytoreductive Total Body Irradiation of Rhesus Monkeys Promotes the Recovery of Immature CD34+ Bone Marrow Cells, Accelerates Platelet, Granulocyte and Red Cell Reconstitution, and Alleviates Neutropenia and Anemia.

HE2100 is characterized as a most potent novel agent to promote stem cell reconstitution and multilineage myelopoiesis after cytoreductive radiation exposure, resulting in enhanced reticulocyte, neutrophil and platelet recovery and profoundly decreased needs for transfusions and antibiotic treatment.

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections, and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.

Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice.

In Vivo Radioprotection by 5-Androstenediol: Stimulation of the Innate Immune System

The results indicate that androstenediol increases the numbers of the three major cell types of the innate immune system (neutrophils, monocytes and NK cells), that and Frostenediol-induced changes in blood elements in irradiated animals persist for at least several weeks, and that there is a significant positive interaction between radiation and administration of androstensiol in the activation of NK cells.

Mobilization of Cutaneous Immunity for Systemic Protection Against Infections

Results indicate that, in vivo, DHEA is not the agent directly mediating the upregulation of the immune response and AED results in markedly greater resistance against both viral and bacterial infection.

The Efficacy of Single-Dose Administration of Thrombopoietin With Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys

It is concluded that a single IV administration of TPO is sufficient to prevent severe thrombocytopenia following myelosuppression and TPO significantly improves the performance of CSFs in alleviating severe neutropenia.

The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.

It is concluded that a single I.V. administration of TPO is sufficient to prevent severe thrombocytopenia following myelosuppression and TPO significantly improves the performance of CSFs in alleviating severe neutropenia.